Nectar Lifesciences per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
−₹11.37−₹13.40−₹5.07₹0.22−₹1.08
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−₹11.37−₹13.40−₹5.07₹0.22−₹1.08
₹29.97₹29.97₹42.63₹47.68₹47.47
₹0.26₹0.00₹74.60₹75.16₹67.98
—−₹17.95₹7.56₹10.02₹5.96
−₹18.58−₹18.58₹5.60₹8.71₹4.62
19.419.422.422.422.4
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NECLIFE₹10.34

Nectar Lifesciences Limited

· Pharma & Health
₹ CrorePeersAAREYDRUGSNATCAPSUQMEDICAMEQMEDICOBALPHARMAALPAKREBSBIOHALEOSLABSMcap ₹201 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS-1.080.22-5.07-13.40-11.37
Diluted EPS-1.080.22-5.07-13.40-11.37
Book Value per Share47.4747.6842.6329.9729.97
Revenue per Share67.9875.1674.600.000.26
Cash Flow per Share5.9610.027.56-17.95—
Free Cash Flow per Share4.628.715.60-18.58-18.58
Shares Outstanding (cr)22.422.422.419.419.4
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.